These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1578145)

  • 1. Heparin and modified heparin inhibit complement activation in vivo.
    Weiler JM; Edens RE; Linhardt RJ; Kapelanski DP
    J Immunol; 1992 May; 148(10):3210-5. PubMed ID: 1578145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum.
    Edens RE; Linhardt RJ; Bell CS; Weiler JM
    Immunopharmacology; 1994; 27(2):145-53. PubMed ID: 8014028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of two types of cobra venom factor on porcine complement activation and pulmonary artery pressure.
    Cheung AK; Parker CJ; Wilcox L
    Clin Exp Immunol; 1989 Nov; 78(2):299-306. PubMed ID: 12412765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of systemic decomplementation with cobra venom factor on corneal complement levels in guinea pigs.
    Pleyer U; Mondino BJ; Sumner HL
    Invest Ophthalmol Vis Sci; 1992 Jun; 33(7):2212-5. PubMed ID: 1607231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of C5 by cobra venom factor is required in neutrophil-mediated lung injury in the rat.
    Till GO; Morganroth ML; Kunkel R; Ward PA
    Am J Pathol; 1987 Oct; 129(1):44-53. PubMed ID: 3661679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional assay of C5-activating and nonactivating cobra venom factor preparations in the mouse system.
    Van den Berg CW; Aerts PC; Van Dijk H
    J Immunol Methods; 1990 Oct; 133(2):199-206. PubMed ID: 2230138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of functionally relevant determinants on the complement component C3 with monoclonal antibodies.
    Burger R; Deubel U; Hadding U; Bitter-Suermann D
    J Immunol; 1982 Nov; 129(5):2042-50. PubMed ID: 6181157
    [No Abstract]   [Full Text] [Related]  

  • 8. The oligosaccharide chains of cobra venom factor are required for complement activation.
    Grier AH; Vogel CW
    Mol Immunol; 1989 Jun; 26(6):563-74. PubMed ID: 2770749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role and mechanism of cobra venom factor-induced suppression of the humoral immune response in guinea pigs.
    Böttger EC; Hoffmann T; Metzger S; Hadding U; Bitter-Suermann D
    J Immunol; 1986 Aug; 137(4):1280-5. PubMed ID: 2942603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement depletion prolongs discordant cardiac xenograft survival in rodents and non-human primates.
    Leventhal JR; Dalmasso AP; Cromwell JW; Manivel CJ; Bolman RM; Matas AJ
    Transplant Proc; 1993 Feb; 25(1 Pt 1):398-9. PubMed ID: 8438352
    [No Abstract]   [Full Text] [Related]  

  • 11. Enhancement of antigen-induced bronchoconstriction after intravascular complement activation with cobra venom factor. Reversal by granulocyte depletion.
    Regal JF; Fraser DG; Anderson DE; Solem LE
    J Immunol; 1993 Apr; 150(8 Pt 1):3496-505. PubMed ID: 8468484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A new low molecular-weight protein effector of human complement from the venom of the Central Asian cobra Naja naja oxiana].
    Kozlov LV; Soliakov LS; Zinchenko AA
    Bioorg Khim; 1984 Mar; 10(3):323-32. PubMed ID: 6567467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echinococcus granulosus: interactions with host complement in secondary infection in mice.
    Díaz A; Ferreira AM; Nieto A
    Exp Parasitol; 1995 May; 80(3):473-82. PubMed ID: 7729482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of murine complement by cobra venom factor in the presence of EDTA.
    Goldman JN; Bangalore S; Goldman MB
    J Immunol; 1979 Nov; 123(5):2421-7. PubMed ID: 114590
    [No Abstract]   [Full Text] [Related]  

  • 15. Complement in the serum and venom of Brazilian snakes (Crotalidae).
    Dias da Silva W; Calich VL; Kipnis TL; Rosen FS; Alper CA
    Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():97-103. PubMed ID: 6587747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naja melanoleuca cobra venom contains two forms of complement-depleting factor (CVF).
    Osipov AV; Mordvintsev DY; Starkov VG; Galebskaya LV; Ryumina EV; Bel'tyukov PP; Kozlov LV; Romanov SV; Doljansky Y; Tsetlin VI; Utkin YN
    Toxicon; 2005 Sep; 46(4):394-403. PubMed ID: 16054663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin and phenprocoumon inhibit kappa-carrageenin induced thrombosis in rats.
    Hirschelmann R; Bekemeier H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(3):379-82. PubMed ID: 2428713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of activated properdin with complexes of properdin with C3.
    Whiteman LY; Purkall DB; Ruddy S
    J Immunol; 1991 Aug; 147(4):1344-51. PubMed ID: 1869827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homogeneous, structurally defined heparin-oligosaccharides with low anticoagulant activity inhibit the generation of the amplification pathway C3 convertase in vitro.
    Linhardt RJ; Rice KG; Kim YS; Engelken JD; Weiler JM
    J Biol Chem; 1988 Sep; 263(26):13090-6. PubMed ID: 3417651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental allergic encephalomyelitis in cobra venom factor-treated and C4-deficient guinea pigs.
    Morariu MA; Dalmasso AP
    Ann Neurol; 1978 Nov; 4(5):427-30. PubMed ID: 83812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.